Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T22:17:28.221Z.
Calculation as of: 2026-10-06T22:17:28.221Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4147f1633fe526555426f89ecb5945f37dfc8ef4561f7e6db8f1148c00751c21
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$5.79B
PS Ratio
17.81
TTM Avg
6.18
3Y Avg
709.08
5Y Avg
947.88
Market Cap
$5.87B
PS Ratio
6.99
TTM Avg
6.09
3Y Avg
5.11
5Y Avg
9.97
Market Cap
$5.95B
PS Ratio
20.48
TTM Avg
18.30
3Y Avg
14.36
5Y Avg
10.80
Market Cap
$5.52B
PS Ratio
1.71
TTM Avg
1.84
3Y Avg
1.84
5Y Avg
1.84
Market Cap
$6.23B
PS Ratio
25.95
TTM Avg
34.19
3Y Avg
32.94
5Y Avg
96.71
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | $5.78B | N/A | N/A | N/A | N/A |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.79B | 17.81 | 6.18 | 709.08 | 947.88 |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.87B | 6.99 | 6.09 | 5.11 | 9.97 |
| GRAIL Inc. (GRAL)vs › | $5.89B | 35.65 | 19.95 | 12.77 | 12.77 |
| CG Oncology Inc. (CGON)vs › | $5.61B | 901.29 | 1844.16 | 3811.91 | 3811.91 |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.95B | 20.48 | 18.30 | 14.36 | 10.80 |
| RadNet, Inc. (RDNT)vs › | $5.53B | 2.44 | 2.51 | 2.38 | 1.82 |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.52B | 1.71 | 1.84 | 1.84 | 1.84 |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.23B | 25.95 | 34.19 | 32.94 | 96.71 |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.32B | 5.27 | 4.89 | 3.61 | 4.09 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-13 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
